Paradigm Biocapital Advisors LP Autolus Therapeutics PLC Transaction History
Paradigm Biocapital Advisors LP
- $2.67 Billion
- Q1 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 6,425,803 shares of AUTL stock, worth $22.4 Million. This represents 1.54% of its overall portfolio holdings.
Number of Shares
6,425,803
Previous 12,611,335
49.05%
Holding current value
$22.4 Million
Previous $81.2 Million
49.52%
% of portfolio
1.54%
Previous 4.22%
Shares
4 transactions
Others Institutions Holding AUTL
# of Institutions
123Shares Held
168MCall Options Held
411KPut Options Held
67.6K-
Syncona Portfolio LTD Guernsey, Channel Islands, X021.3MShares$74.3 Million90.76% of portfolio
-
Blackstone Inc New York, NY20.5MShares$71.3 Million0.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$53.1 Million3.22% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$43 Million0.95% of portfolio
-
Wellington Management Group LLP Boston, MA10.8MShares$37.5 Million0.01% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $316M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...